PLD vs. observation for advanced soft tissue sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced soft tissue sarcoma (certain rare subtypes are not included).
- You finished 4 to 8 cycles of your first chemotherapy (anthracycline type).
- Your best response to that chemo was complete or partial shrinking, or stable disease.
- You start the trial within 8 weeks of your last chemo dose.
- You are 18 or older and have good physical function (ECOG 0 or 1).
- Your organs are working well (heart, liver, kidneys, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This study tests a combination of two drugs (anlotinib and bempegaldesleukin) plus standard chemotherapy and radiation for people with advanced soft tissue sarcoma that has spread or can't be removed. The goal is to see if this combination helps shrink tumors and control the cancer.
This study tests whether adding an investigational drug called BOLD-100 to a standard chemotherapy (doxorubicin) helps people with certain types of advanced soft tissue sarcoma. It might slow tumor growth or shrink tumors.
This trial tests whether adding a new drug called DT-7012 to standard chemotherapy (doxorubicin) works better than chemotherapy alone for two types of advanced soft tissue sarcoma. It aims to see if the combination can shrink tumors or slow their growth.
Hear when a new Advanced Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.